The Implications of Brexit on the Pharmaceutical, Medical Devices & Clinical Trials Sectors

Acorn Regulatory has published a whitepaper looking at the potential implications of Brexit on a number of healthcare sectors.  The document looks at the impact of the UK’s decision to leave the EU on institutions such as the EMA.  It also focuses on the EU’s Medical Device Directive and the regulations surrounding clinical trials.

The Implications of Brexit on the Pharmaceutical, Medical Devices & Clinical Trials Sectors whitepaper cover

Speaking at the launch of the document, Managing Director of Acorn Regulatory Dr. Gemma Robinson said “There is now great uncertainty for the industry sectors that we cover.  Questions about appropriate regulatory strategies, potential differences in regulatory frameworks, the relocation of the European Medicines Agency, loss of a powerful national competent authority all hang in doubt.  This briefing document aims to throw light on what Acorn Regulatory sectoral experts know now and what they believe will happen”.

This is the first document in a series of whitepapers on the ‘Brexit’ issue. Acorn Regulatory will publish further documents as the negotiations for the UK to leave the EU begin to shed light on what may happen in these very important sectors.

Read the whitepaper on the implications of Brexit by completing the details below: